Cantor Fitzgerald Decreases Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN) – Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for AxoGen in a research note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst R. Osborn now expects that the medical equipment provider will post earnings per share of $0.07 for the year, down from their previous forecast of $0.19. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group raised their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday.

AxoGen Price Performance

AXGN stock opened at $20.01 on Friday. AxoGen has a 52-week low of $5.55 and a 52-week high of $21.00. The stock’s fifty day simple moving average is $17.75 and its 200-day simple moving average is $15.08. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $880.60 million, a price-to-earnings ratio of -62.53 and a beta of 1.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. First Light Asset Management LLC raised its position in shares of AxoGen by 10.2% in the 4th quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider’s stock worth $74,272,000 after buying an additional 416,499 shares during the period. Geode Capital Management LLC raised its position in shares of AxoGen by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock worth $14,170,000 after buying an additional 31,612 shares during the period. Driehaus Capital Management LLC raised its position in shares of AxoGen by 166.0% in the 4th quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider’s stock worth $15,729,000 after buying an additional 595,579 shares during the period. State Street Corp raised its position in shares of AxoGen by 11.9% in the 3rd quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock worth $12,571,000 after buying an additional 95,051 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in AxoGen by 13.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider’s stock valued at $12,735,000 after purchasing an additional 91,984 shares during the period. 80.29% of the stock is owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.